Topics

Sunesis nets $23.5mm through public offering of common and preferred shares

15:40 EDT 12 Jul 2019 | Elsevier Business Intelligence

Sunesis Pharmaceuticals Inc. (treatments for blood and solid cancers) netted $23.5mm through a public offering of common and ...

Original Article: Sunesis nets $23.5mm through public offering of common and preferred shares

NEXT ARTICLE

More From BioPortfolio on "Sunesis nets $23.5mm through public offering of common and preferred shares"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...